雷贝拉唑联合硫糖铝治疗活动性胃溃疡78例

目的研究探讨雷贝拉唑联合硫糖铝治疗Hp感染活动期胃溃疡的临床疗效。方法选取2010年10月-2012年8月期间我院收治的活动性胃溃疡患者156例，随机分为观察组和对照组，各78例。第1周两组患者均接受标准3联疗法根除Hp，第2-8周观察组给予雷贝拉唑联合硫糖铝；对照组给予雷贝拉唑治疗。疗程结束后行胃镜及病理检查，随诊所有患者1年溃疡复发率。结果治疗8周后，两组患者的临床症状和溃疡情况均得到显著改善，组问差异无统计学意义（P〉O．05）；观察组在1年内的溃疡复发率（14．1％）明显低于对照组（35．9％），差异有统计学意义（P〈0．05）。结论雷贝拉唑联合硫糖铝治疗活动胜胃溃疡安全有效，复发率低，值得临床推广应用。

Rabeprazole joint sucralfate treatment of active gastric ulcer 78 cases

Objective To study investigated the combination of rabeprazole treatment of Hp infection sucralfate active ulcer clini- cal efficacy. Methods October 2010 to August 2012 in our hospital during the activity of 156 cases of gastric ulcer patients were randomly divided into observation group and control group, 78 cases. Week 1 patients received combination therapy to eradicate Standard 3 Hp, the first 2-8 weeks of rabeprazole joint observation group were given sucralfate; control group were given rabepra- zole treatment. End of treatment underwent endoscopy and biopsy, all patients were followed up for 1 year ulcer recurrence rate. Results After 8 weeks, both groups of patients with clinical symptoms and ulcers circumstances were improved significantly be- tween the two groups showed no significant difference （P〉0.05）; observation group in a year ulcer recurrence rate was significantly lower than the control group, the difference there was statistically significant （P〈O.05）. Conclusion The combination of sucralfate rabeprazole treatment of active gastric ulcer effect is significant, recurrence rate, worthy of clinical application.